Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Charu Aggarwal, MD, MPH
Alexander Drilon, MD
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Sagar Lonial, MD, FACP
Caitlin Costello, MD
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Intracranial Activity of ROS1 TKIs
Integrating Bispecific Antibodies Into Clinical Practice
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Considerations for Dosing Bispecific Antibodies
Clinical Challenges With Triple-Class or Penta-Refractory MM
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.